Inflammatory markers in chronic obstructive pulmonary disease patients with different α1 antitrypsin genotypes

Archives of Medical Science

Volumn 8, Issue 6, 2012, Pages 1053-1058

  Serapinas, Danielius ^a,b   Sitkauskiene, Brigita ^a   Sakalauskas, Raimundas ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b MYKOLAS ROMERIS UNIVERSITY   (Lithuania)

Author keywords

1 antitrypsin; Chronic obstructive pulmonary disease; Inflammatory markers

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CD14 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ALPHA ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATION ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENOTYPE; HUMAN; ISOELECTRIC FOCUSING; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN BLOOD LEVEL;

EID: 84873107482     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.32414     Document Type: Article

References (45)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2006). Global strategy for the diagnosis, management, and prevention of COPD, Executive Summary. Date last accessed: August 2008.
2. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002;57:1067-70. (Pubitemid 35440768)
3. Chung K F. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006;7:675-81. (Pubitemid 43827263)
4. Gan WQ, Man S F P, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80. (Pubitemid 38901515)
5. Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers, and nonsmokers. Thorax 2006;61:23-8. (Pubitemid 43106973)
6. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007;13:37-43. (Pubitemid 46122972)
7. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008;19:104-8.
8. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008;214:149-60. (Pubitemid 351160153)
9. American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818-900.
10. Janoff A, Sloan B, Weinbaum G, et al. Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. Am Rev Respir Dis 1977;115:461-78. (Pubitemid 8064149)
11. Hadzic R, Nita I, Tassidis H, Riesbeck K, Wingren AG, Janciauskiene S. Alpha-1 antitrypsin inhibits Moraxella catarrhalis MID protein-induced tonsillar B cell proliferation and IL-6 release. Immunol Lett 2006;102:141-7. (Pubitemid 43053083)
12. Watt AP, Schock BC, Ennis M. Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr Drug Targets Inflamm Allergy 2005;4:415-23. (Pubitemid 41052406)
13. Van Der Vaart H, Postma DS, Timens W, et al. Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res 2005;6:22.
14. Mulgrew A, Taggart CC, Lawless MW, et al. Alpha-1 Antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004;125:1952-7. (Pubitemid 38648435)
15. Janciauskiene SM, Stevens T, Blanco I. New insights into the biology of α1-antitrypsin and its role in chronic obstructive pulmonary disease. Curr Respir Med Rev 2007;3:147-58. (Pubitemid 46773922)
16. Nita IM, Serapinas D, Janciauskiene SM. Alpha1-Antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int J Biochem Cell Biol 2007;39:1165-76. (Pubitemid 46819133)
17. Pierce JA, Eradio BG. Improved identification of antitrypsin phenotypes through isoelectric focusing with dithioerythritol. J Lab Clin Med 1979;94:826-31. (Pubitemid 10171549)
18. Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010;11:63.
19. Senn O, Russi EW, Schindler C, et al. Circulating alpha1-antitrypsin in the general population: determinants and association with lung function. Respir Res 2008;9:35.
20. Engström G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammationsensitive plasma proteins. Circulation 2002;106:2555-60. (Pubitemid 35340691)
21. Welle I, Bakke PS, Eide GE, Fagerhol MK, Omenaas E, Gulsvik A. Increased circulating levels of alpha1-antitrypsin and calprotectin are associated with reduced gas diffusion in the lungs. Eur Respir J 2001;17:1105-11. (Pubitemid 32717465)
22. Stockley RA, Burnett D. Alpha1-antitrypsin and leukocyte elastase in infected and non-infected sputum. Am Rev Respir Dis 1979;120:1081-6. (Pubitemid 10218496)
23. Owen CA, Campbell EJ. Extra-cellular proteolysis: new paradigms for an old paradox. J Lab Clin Med 1999;134:341-51. (Pubitemid 29490153)
24. Higashimoto Y, Yamagata Y, Taya S, Iwata T, Okada M, Ishiguchi T. Systemic inflammation in chronic obstructive pulmonary disease and asthma: similarities and differences. Respirology 2008;13:128-33.
25. Meyer KC, Rosenthal NS, Soergel P, Peterson K. Neutrophils and low-grade inflammation in the seemingly normal aging human lung. Mech Ageing Dev 1998;104:169-81. (Pubitemid 28457047)
26. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax 2004;59:574-80. (Pubitemid 38901515)
27. Silverman EK, Province MA, Rao DC, Pierce JA, Campbell EJ. A family study of the variability of pulmonary function in alpha 1-antitrypsin deficiency. Quantitative phenotypes. Am Rev Respir Dis 1990;142:1015-21. (Pubitemid 20384352)
28. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-88. (Pubitemid 37258549)
29. Sin DD, Man S F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9. (Pubitemid 36378490)
30. Shaaban R, Kony S, Driss F, et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal populationbased study. Respir Med 2006;100:2112-20. (Pubitemid 44752671)
31. Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neu-Kirch F. Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax 2004;59:892-6. (Pubitemid 39389631)
32. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun 2001;69:1747-54. (Pubitemid 32187634)
33. Van Eeden SF, Tan WC, Suwa T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM10). Am J Respir Crit Care Med 2001;164:826-30. (Pubitemid 32881920)
34. Sin DD, Lacy P, York E, Man S F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-5. (Pubitemid 39298991)
35. Lessiani G, Falco A, Franzone G, Saggini R, Davi G. Prevalence of deep vein thrombosis in patients affected by exacerbation of mild to moderate COPD at stage I-II of GOLD classification. Arch Med Sci 2008;4:62-5. (Pubitemid 351588824)
36. Janciauskiene SM, Nita IM, Stevens T. Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro antiinflammatory activity in human monocytes by elevating cAMP. J Biol Chem 2007;282:8573-82. (Pubitemid 47093518)
37. Libert C, Van Molle W, Brouckaert P, Fiers W. Alpha1-Antitrypsin inhibits the lethal response to TNF in mice. J Immunol 1996;157:5126-9. (Pubitemid 126449595)
38. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB, Temel I. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006;100:846-54.
39. Hollander C, Sitkauskiene B, Westin U, Sakalauskas R, Janciauskiene SM. Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. Respir Med 2007;101:1947-53. (Pubitemid 47163535)
40. Katakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Bar-Nes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532-9.
41. Rutgers SR, Postam DS, Ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-8. (Pubitemid 30248773)
42. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007;62:595-601. (Pubitemid 47056886)
43. Martin TR, Rubenfeld GD, Ruzinski JT, et al. Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory distress sindrome. Am J Respir Crit Care Med 1997;155:937-44. (Pubitemid 27133406)
44. Sandström CS, Novoradovskaya N, Cilio CM, Piitulainen E, Sveger T, Janciauskiene S. Endotoxin receptor CD14 in PiZ alpha-1-antitrypsin deficiency individuals. Respir Res 2008;9:34.
45. Molfino NA. Current thinking on genetics of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2007;13:107-13. (Pubitemid 46175106)